Copyright © 2004 by the European Society of Cardiology.
Clinical research
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS
a Erasmus Medical Center, University Hospital Rotterdam, Room H 560, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
b Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada
c Centocor Inc., Malvern, Pennsylvania, USA
d Duke University Medical Center, Durham, USA
e Department of Cardiology, Uppsala, Sweden
Received September 2, 2003; revised June 28, 2004; accepted July 1, 2004 * Corresponding author. Tel.: +31 104633938; fax: +31 104635258 (E-mail: m.simoons{at}erasmusmc.nl).
See page 1471 for the editorial comment on this article (doi:10.1016/j.ehj.2004.05.019)
BACKGROUND: Immediate, as well as early, revascularisation is of benefit in patients with acute coronary syndromes (ACS) presenting with ST elevation. However, trials comparing invasive versus medical treatment in patients with an acute coronary syndrome without ST elevation do not consistently show improvement in survival after revascularisation. Accordingly, additional data are warranted.
METHODS: The effect of revascularisation within 30 days on one-year survival in the GUSTO IV ACS trial was investigated. A total of 7800 patients were included with an acute coronary syndrome without ST elevation, documented by either elevated cardiac troponin or transient or persistent ST-segment depression. In this trial, comparing abciximab versus placebo as initial medical therapy, coronary angiography within 60 h after randomisation was discouraged. In 30-day survivors, those who underwent revascularisation were compared with 30-day survivors without revascularisation. Adjustments were made for patient characteristics, and for a propensity score that was adjusted for covariates associated with the likelihood of early revascularisation.
FINDINGS: Of the 7496 patients who survived at least 30 days, 2265 (30%) underwent coronary revascularisation within 30 days: 789 patients CABG, 1450 PCI and 26 both CABG and PCI. Procedure-related mortality was low at 1.8%. Patients with revascularisation had a lower one-year mortality compared to medically treated patients (2.3% vs. 5.6%, p<0.001). After multivariable analyses, patients with revascularisation had a relative risk of subsequent mortality within 1 year of 0.53 (95% CI 0.37–0.77) compared to patients without revascularisation.
CONCLUSIONS: Revascularisation within 30 days is associated with an improved prognosis in ACS without ST-segment elevation. The relative high mortality in medically treated patients may be related in part to patient selection, but warrants further studies to improve outcome of these patients.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Revascularisation for everyone?
- Christopher P. Cannon
EHJ 2004 25: 1471-1472.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. Hirsch, F. Windhausen, J. G.P. Tijssen, A. J.M. Oude Ophuis, W. J. van der Giessen, P. M. van der Zee, J. H. Cornel, F. W.A. Verheugt, R. J. de Winter, and for the Invasive versus Conservative Treatment in Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias Eur. Heart J., March 2, 2009; 30(6): 645 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Held, P. Tornvall, and U. Stenestrand Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery Eur. Heart J., February 1, 2007; 28(3): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. James, J. Lindback, J. Tilly, A. Siegbahn, P. Venge, P. Armstrong, R. Califf, M. L. Simoons, L. Wallentin, and B. Lindahl Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality Benefit From Coronary Revascularization in Acute Coronary Syndromes: A GUSTO-IV Substudy J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1146 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Monteiro and on behalf of the Portuguese Registry on Acute Coro Impact of Early Coronary Artery Bypass Graft in an Unselected Acute Coronary Syndrome Patient Population Circulation, July 4, 2006; 114(1_suppl): I-467 - I-472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kilickap, I. Barista, and K. Aytemir Reply to "Troponins in prediction of cardiotoxic effects", by D. Cardinale et al. Ann. Onc., January 1, 2006; 17(1): 173 - 174. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|